NCT03353051

Brief Summary

The motivation for this study was produced from our preliminary data, which showed that during the first 96 hours of life a full-term neonate will actively reduce the overall serum iron concentration of their blood and the transferrin saturation decreases rapidly from 45% in cord blood to \~20% by six hours post-delivery. The Investigators hypothesise that this active sequestration of iron, which results in hypoferremia, is done in an effort to limit susceptibility to infection, a process referred to as nutritional immunity. Currently, little is known about iron regulation and iron homeostasis during the first week of life and even less is known about the comparisons of nutritional immunity between full term, preterm and low birth weight neonates. Additionally, limited research has been conducted on the impact of these processes on bacterial pathogens. In an effort to study the neonatal nutritional immunity and its role in neonatal susceptibility to infection, The investigator will conduct an observational study in full-term, preterm and low birth weight vaginally-delivered neonates born at Serrekunda General Hospital, The Gambia. The investigators will fully characterise and quantify nutritional immunity during the early neonatal period and the investogators will assess how this impacts bacterial growth. Study sensitisation will occur at the antenatal clinic, during the mother's second trimester of pregnancy. Mothers will be consented and enrolled at delivery. Blood samples will be collected once from the umbilical cord and at serial time points from the neonates over the first week of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
430

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2017

Completed
5 days until next milestone

Study Start

First participant enrolled

July 25, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 27, 2017

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 21, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 3, 2019

Completed
Last Updated

February 24, 2020

Status Verified

February 1, 2020

Enrollment Period

1.3 years

First QC Date

July 20, 2017

Last Update Submit

February 21, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • serum iron

    will be measured using a COBAS INTEGRA 400 plus clinical chemistry analyzer

    at 7 days after birth

Secondary Outcomes (3)

  • TSAT (%) and heme iron (mg/dL)

    at 6 hours after birth

  • Iron (ug/dL), TSAT (%) and heme iron (mg/dL) regulated regulation in FT neonates

    7 days after birth

  • microorganisms that are common causes of neonatal sepsis

    At 0, 6 and 24 hours after birth

Study Arms (6)

Group A: other - observational study

neonates ≥2000-\<2500g and born with a gestation age \<37 weeks.

Other: Observational study

Group B: other- observational study

Group B will contain neonates \>2500g and born with a gestation age \<37 weeks.

Other: Observational study

Group C: other - observational study

Group C will contain neonates ≥2000-\<2500g but with a gestation age \>37 weeks.

Other: Observational study

Group D1:other - observational study

Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.

Other: Observational study

Group D2: other - observational study

Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs

Other: Observational study

Group D3: other - observational study

Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.

Other: Observational study

Interventions

Observational study

Group A: other - observational studyGroup B: other- observational studyGroup C: other - observational studyGroup D1:other - observational studyGroup D2: other - observational studyGroup D3: other - observational study

Eligibility Criteria

Age5 Minutes - 28 Days
Sexall
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

All neonates will be born at Serrekunda Hospital, The Gambia. New Ballard score is only measure used to evaluate gestational age Preterm neonates with Low Birth Weight (PTB with LBW) (Group A): Neonates will not be recruited directly into this group. These medical stable neonates will weigh \<2500g and also be \<37 weeks of gestational age. Preterm (PTB) neonates (Group B): Medical stable neonates between \>32 and \<37 weeks' gestational age. PTB neonates will weigh \>2500g. Low Birth Weight (LBW) neonates (Group C): Medical stable neonates with weight equal to or \>2000g and \<2500g. LBW neonates will have a gestational age of \>32 weeks. Full Term (FT) neonates (Group D1-D3): All healthy FT neonates will weigh ≥2500g with gestational age ≥37 weeks.

You may qualify if:

  • Low Birth Weight (LBW) neonates:
  • Medical stable neonates
  • Neonatal weight ≥2000g and \<2500g
  • Born at Serrekunda Hospital
  • Gestational age will be \>37 weeks.
  • Born to mothers at least 18 years of age
  • Preterm neonates with Low Birth Weight (PTB+LBW):
  • Medical stable neonates
  • Born at Serrekunda Hospital
  • Neonates weighing \<2500g and \<37 weeks of gestational age.
  • Born to mothers at least 18 years of age
  • Preterm (PTB) neonates:
  • Medical stable neonates
  • \>32 and \<37 weeks' gestational age
  • Born at Serrekunda Hospital
  • +8 more criteria

You may not qualify if:

  • Major congenital malformations
  • Severe birth asphyxia
  • Children from multiple births
  • Medication (i.e. prophylactic antibiotics) given to neonate before first neonatal venous blood draw
  • Neonates born via Breech, Vacuum or C section
  • Neonates with infection/illness (information gained from venous bleed) will no longer be required to give future samples if originally required

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Serrekunda General Hospital

Kanifing, Near Banjul, The Gambia

Location

Related Publications (3)

  • Cross JH, Jarjou O, Mohammed NI, Gomez SR, Touray BJB, Kessler NJ, Prentice AM, Cerami C. Iron homeostasis in full-term, normal birthweight Gambian neonates over the first week of life. Sci Rep. 2023 Jun 26;13(1):10349. doi: 10.1038/s41598-023-34592-z.

  • Cross JH, Jarjou O, Mohammed NI, Rayment Gomez S, Touray BJB, Prentice AM, Cerami C. Early postnatal hypoferremia in low birthweight and preterm babies: A prospective cohort study in hospital-delivered Gambian neonates. EBioMedicine. 2020 Feb;52:102613. doi: 10.1016/j.ebiom.2019.102613. Epub 2020 Jan 22.

  • Cross JH, Jarjou O, Mohammed NI, Prentice AM, Cerami C. Neonatal iron distribution and infection susceptibility in full term, preterm and low birthweight babies in urban Gambia: study protocol for an observational study. Gates Open Res. 2019 Oct 15;3:1469. doi: 10.12688/gatesopenres.12963.2. eCollection 2019.

Biospecimen

Retention: SAMPLES WITH DNA

Serum will be kept for follow up analysis if further iron and inflammation parameters require quantification. G6PD deficiency and sickle cell disease are confounders in the bacterial growth assay. G6PD deficiency genetic test will be performed on whole blood. Sickle cell will be assessed by PCR. Samples will be saved for additional possible DNA analysis.

MeSH Terms

Interventions

Observation

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Carla Cerami, MD, PhD

    Medical Council Unit the Gambia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2017

First Posted

November 27, 2017

Study Start

July 25, 2017

Primary Completion

November 21, 2018

Study Completion

April 3, 2019

Last Updated

February 24, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations